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Background & Objective: Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12) 
is a relatively common subtype of acute myeloid leukemia (AML).  Here, our objective 
was to ascertain the survival of patients with this leukemia in north-east of Iran. 
Methods: Survival rates of 42 APL patients with t(15;17)(q22;q12) were assessed. Clinical 
information was obtained from archived medical records. Statistical analysis was performed by 
SPSS 18 software using log-ranked test and Kaplan Maier survival analysis. 
Results: Females and males comprised 49% and 51%, respectively. The mean age at 
diagnosis was 34.3±14.1 years old. During the study period, 17 demises occurred in 
males, while this number was 7 in females. The mean survival of patients (month) was 
23.22±3.57 (95% CI: 16.21±30.2).  The five-year survival rate obtained 30%. 
Regarding demographic and clinical features, the highest rates of 5-year survival were 
recorded in patients with 20-35 years old (47.6%), males (51%), white blood cell count 
<10× 109 /l (48%), and platelet count >140× 109/l (100%).  
Conclusion: Younger age, lower WBC count and higher platelet count were significantly 
associated with longer survival in AML patients with t(15;17)(q22; q12). 
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Introduction
Incidence of hematological malignancies has 
elevated in recent decades (1). Acute leukemia 
accounts for approximately 20,000 of cancers 
diagnosed annually in the United States (2). Acute 
lymphoblastic leukemia (ALL) and acute myeloid 
leukemia (AML) constitute two principal categories of 
acute leukemia. Acute promyelocytic leukemia (APL) 
is a subtype of AML which is characterized by 
proliferation of malignant promyelocytes within blood 
and bone marrow.  APL, comprising 5-8% of AML 
cases, is a unique form of AML regarding its strong 
association with the development of intravascular 
coagulation. Although clinically aggressive, APL is 
one of the most curable forms of AML which is 
sensitive to all-trans-retinoic acid (ATRA) (3). APL 
arises at a younger age, has a peak during adolescence 
and then reaches a plateau in early adulthood (4). APL 
represents M3 morphological subtype of French-
British-American (FAB) classification system and is 
currently categorized as APL with translocation 
t(15;17) (q24.1;q21.1) by world health organization 
(WHO) (5).  
At cytogenetic level, 98% of APL cases are 
characterized by t (15;17)(q22;q12). This diagnostic 
feature may be confirmed by Fluorescence in situ 
hybridization (FISH) or by real-time PCR to detect 
Promyelocytic leukemia gene/ Retinoic Acid Receptor 
Alpha (PML-RARA) fusion gene (6). RARA gene is 
located at 17q21, and encodes a myeloid transcription 
factor. The expression of chimeric protein PML-
RARA suppresses transcription of specific tumor 
suppressors favoring progression of APL. Rarely, 
RARA may be fused with genes other than PML. The 
alternative variant partners of RARA include PLZF 
(ZBTB16), NPM1 and STAT5b (7,8). The clinical 
importance of RARA fusion partners lies within 
differential responses to targeted therapies 
necessitating detection of classical t(15;17)(q22;q12). 
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ATRA and arsenic trioxide (ATO) are current 
medications for t(15;17)(q22;q12) positive AML. 
While ATO generally promotes favorable responses 
only in cases with PML-RARA fusion, ATRA is also 
effective in cases with NPM1, NUMA and FIP1L1 
fusion partners (9-11).   
Survival studies in patients with hematologic 
malignancies provide valuable insights into the 
identification of parameters associated with high 
mortalities and also provide us with opportunities to 
improve life expectancy of at-risk patients. Such 
studies help clinicians and researchers to develop a 
database providing essential information about the 
current updates on prognostic factors. To the best of 
our knowledge, there is no report regarding survival 
and prognostic features of APL patients in north-east 
of Iran. In the present study, survival analysis was 
performed on AML patients detected with 
t(15;17)(q22;q12) at Molecular Pathology Research 
Center of Qaem hospital, Mashhad city of Iran. 
 
     Materials and Methods 
 
Patients 
This was an epidemiological study performed 
during 2010-2015. The study was financially 
supported by the Molecular Pathology Research 
Center affiliated with Mashhad University of medical 
sciences. Our study was approved by the ethics 
committee of Mashhad University of medical sciences 
(Ethical code: A_908). 
Our cohort constituted of 240 AML cases diagnosed 
at hematology department of Qaem hospital of 
Mashhad city. Clinical and laboratory information 
about 42 patients with positive t(15;17)(q22;q12) by 
routine karyotyping was gathered from available 
medical records at our center. Clinical symptoms and 
complete blood count parameters were documented at 
presentation before initiation of any treatment. The 
sample size was calculated considering 10% of the total 
population of AML with t(15;17), 95% confidence 
interval, and 0.05 standard error. Five-year survival 
rates for patients diagnosed with t(15;17)(q22;q12) 
were further documented by phone interviews. 
The diagnosis was further scrutinized by observing 
abnormal promyelocytes in blood or bone marrow, 
staining bone marrow aspirations or peripheral blood 
smears for myeloperoxidase and investigating positive 
results for CD13, CD33, CD15 and CD 117 markers by 
flow cytometry. PML-RARA fusion gene was revealed 
by real-time PCR as well. Patients who received any 
treatments before the study initiation and patients with 
relapsed disease were excluded from the study. 
The therapeutic protocol was according to the 
standard chemotherapy regimen for APL. Patients 
received a combination of Daunorubicin, cytarabine, 
and ATRA for both induction and consolidation 
therapies. For patients who acquired remissions, 
maintenance therapy was continued with ATRA. 
Administration of antibiotics was performed for 
those with low white blood cell count. Blood products 
(packed red blood cells, and platelets) were given to 
eligible patients (patients with symptomatic anemia, 
and those at risk of bleeding due to low platelet count). 
Pain relieving agents were generally administered for 
patients with chronic pain.     
RNA Extraction 
Separation of mononuclear cells from bone marrow 
aspirated samples was carried out using Ficoll gradient 
centrifugation. RNA was extracted by Tri-Pure (Roche, 
Germany) according to standard instructions provided 
by the manufacture. Quality of extracted RNA was 
checked by agarose electrophoresis on 2% agarose gel. 
cDNA Synthesis 
cDNA synthesis kit was purchased from Fermentas 
(RevertAid™ H Minus First Strand cDNA Synthesis, 
USA), and the procedure was performed according to 
the manufacturer’s instructions. 
Detection of PML-RARA Fusion Gene 
Real time PCR was carried out by an ABI 
thermocycler (Applied Biosystems, USA) in duplicate 
assays using Taqman. Sequences of specific primers 
and probes for fusion PML-RARA transcripts of three 
Break point Cluster Regions (BCR) were as forward 
primers; 5′-TCTTCCTGCCCAACAGCA -3', 5′-
ACCTGGATGGACCGCCTA -3′ and 5′-
CCGATGGCTTCGACGAGT -3′, and reverse primer; 
5′-GCTTGTAGATGCGGGGTAGAG -3′.  Specific 
probe exploited was 5′ Fam-AGTGCC 
CAGCCCTCCCTCGC-Tamara-3′. ABL served as the 
reference gene with primer sequences of forward: 5′- 
TGGAGATAACACTCTAAGCATAACTAAAGGT-
3′ and reverse; 5′- GATGTAGTTGCTTGGGACCCA-
3′, with Specific probe of FAM-
CCATTTTTGGTTTGGGCTTCACACCATT- 
Tamara. Each reaction tube contained 10 µL pre-mix 
Taqman, 0.5 µL ROX dye, 1.5 µL of each forward and 
reverse primers (10 pmol), 1.5 µL of specific probes, 2 
µL of cDNA, and 3 µL of DEPC water. Thermal profile 
was set as initial denaturation (95℃) for 30 seconds and 
then 40 cycles of PCR phases as denaturation (95℃, 40 
seconds), annealing (60℃, 32 seconds) and extension 
(72℃, 60 seconds). 
Two types of positive controls (positive control of 
REH cell line, Biomed Reference, and a patient’s 
sample confirmed with positive PML-RARA), and two 
types of negative controls (negative sample from 
known patients, and NTC) were used. Positive results 
were inferred as the presence of amplification curve at 
CT of 20-27.9 cycles, and negative results were 
considered as the absence of amplification curve at 
CT<36. The CT of the control gene was 23.5-27.7. 
Statistical Analysis 
Statistical analysis was performed in SPSS 18 
(SPSS Inc., Chicago, Ill., USA). Descriptive statistics 
were used to analyze general demographic and 
laboratory features. Kaplan Mayer survival analysis 
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was performed to assess 5-year survival in 
t(15;17)(q22;q12) positive patients.  
 
     Results 
From a total of 240 AML patients diagnosed 
according to standard procedures, 42 cases (17.5%) 
showed t(15;17)(q22;q12). The median age in t(15;17) 
negative group was 31.68+20.56 years old. In terms of 
sex, 49% were females and 51% were males. For 
patients with positive t(15;17), the mean age was 
34.3+14.1 years old. Regarding age at diagnosis, 11.9% 
of these patients had <20 years old, 47.6% with 20-35 
years old, 28.5% with 35-50 years old, and 11.9% had 
>50 years old. Of these, 35.7% were males and 64.3% 
were females. Characteristics of t(15;17)(q22;q12) 
negative and positive AML patients have been 
demonstrated in Tables 1 and 2, respectively. 
Splenomegaly and hepatomegaly were the most 
common clinical features, each was present at 28.6% of 
patients. All patients had at least two of symptoms 
including fever, anemia, petechia, oral bleeding, 
menorrhagia or CNS involvement upon admission. 
Overall, 24 demises were observed. Death 
occurrence statistics were as follows; 3 in patients <20 
years old, 11 in those with 20-35 years old, 8 in patients 
with 35-50 years old, and 2 in cases with >50 years old.  
Considering sex, 17 deaths occurred in males and 7 in 
females during the study period. Death occurrence in 
patients with WBC of <10× 109/𝑙 , 10-49.9× 109/𝑙, 
50-100× 109/𝑙, and >100× 109/𝑙 were 9, 11, 2, and 2 
respectively. Regarding platelet count, death rates were 
22, 2, and 0 cases in groups with <70× 109/𝑙, 70-
140× 109/𝑙, and >140 × 109/𝑙 respectively. 
Median of 5-year survival in AML patients with 
t(15;17)(q22;q12) was obtained 23.22+3.57 month 
(95%CI: 16.21-30.29) with a 5-survial survival rate of 
30%. Patients with positive t(15;17)(q22;q12) were 
subcategorized into four age groups; <20 years old, 20-
35 years old, 36-50 years old, and >50 years old, each 
with respective 5-year survival rates of 11.9%, 47.6%, 
28.5%, and 11.9%. Five-year survival rates based on 
the investigated features have been illustrated in Table 
3, and Figure 1. 
 
Table 1. Demographic and clinical characteristics of t(15;17)(q22;q12) negative and positive  AML  patients. 












 t(15;17)(q22;q12)  patients positive AML 
Total= 42  
 
N(%) 
Gender Male 27(64.3) 




Bleeding 29 (69%) 




Table 2. Features of AML patients with and without t(15;17)(q22;q12) cytogenetic abnormality. 
 t(15;17)(q22;q12) negative AML AML with t(15;17) (q22;q12)  patients 
 Mean±SD Minimum Maximum Mean±SD Minimum Maximum 
Age (years) 31.6±20.5 1 78 34.3±14.1 4 70 
WBC (× 𝟏𝟎𝟗/𝒍) 33500±42923 400 233000 24200±34410 600 156000 
RBC (× 𝟏𝟎𝟏𝟐/𝒖𝒍) 2.9±1.5 0.2 22.2 2.7±0.6 1.2 4.3 
Hematocrit (%) 25.3±6 2.3 40.3 24.5±5.5 11.5 41 
Hemoglobin (g/dl) 8±2 0.7 13.7 8.2±1.7 3.7 12.9 
Platelet (× 𝟏𝟎𝟗/𝒍) 72100±68193.5 3000 415000 49400±70189 8000 414000 
A                                                                                                B 
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Fig. 1. Kaplan-Meier survival curves in patient with t(15;17)(q22;q12) positive AML. A) based on age groups, B) based on gender, 
C) based on platelet count, D) based on white blood cell count, and E) overall survival rate 
 













<20 5 (11.9) 11.9 14.2±6.2 2-26.5 
20-35 20 (47.7) 47.6 22.2±4.4 13.4-30.9 
35-50 12 (28.5) 28.5 20.2±6.6 7.1-33.3 
>50 5 (11.9) 11.9 30.8±10.9 9.3-52.2 
Gender Male 27 (64.3) 51 27.5±6.4 14.9-40.2 
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Female 15(35.7) 19.2 19.9±3.7 12.6-27.2 




<10 21 (50) 48 29.7±5.2 19.5-40 
10-50 16 (38) 24.6 16.9±4.5 8-25.9 
50-100 3 (7.1) 0 5.1±1.8 1.5-8.6 
>100 2 (4.9) 0 13±9 4.7-30.7 
Platelet 
<70 37 (88) 29.3 21.1±3.8 13.6-28.5 
70-140 3 (7.1) 64.2 25±7.2 10.8-39.2 
>140 2 (4.9) 100 51.1 51.1-51.1 
 
Discussion
In the current study, we evaluated 5-year survival 
rates of AML patients with t(15;17)(q22;q12) in north-
east of Iran. Among 240 patients who diagnosed with 
AML during the study period, 42 (17.5%) were 
recognized with t(15;17)(q22;q12). In addition, 
frequencies of t(8;21)(q22;q22), and Inv (16) (p13; q22) 
subtypes of AML were 7.6% and 6.6% respectively, 
while no cytogenetic abnormalities were diagnosed in 
170/240 (70.8%).  
Kamaneh et al. evaluated 46 AML patients in north-
west of Iran. Their findings showed that only 2.7% of 
patients harbored t(15;17)(q22;q12) (12). However, in a 
recent study conducted by Allahyari A et al. in the north-
east part of Iran, t(15;17) subtype of AML was the most 
prevalent category with 37.7% (13). The incidence of 
APL was shown to increase from 1975 towards 2008 in 
the United States (14).  
Overall, we recorded a 5-year survival rate of 30% 
for t(15;17)(q22;q12) positive AML patients, with 
median survival of 23.22+3.57 months. Similarly, 
Allahyari et al. reported 5-year overall survival of 26.6% 
in 96 AML patients from the north-east part of Iran (13). 
The lower survival rate in their study may be due to the 
higher mean age of their patients (mean age of 40.4 years 
old). Furthermore, the study of Allahyari et al. was 
performed on various subtypes of AML rather than only 
APL. In a study on 95 AML patients in Iran, median 
overall survival was reported 13 months, with one-year 
and two-year survival rates of 51% and 26% respectively 
(15). This was considerably lower than the survival 
observed in our study which may be due to the 
heterogeneity of AML subtypes in the before mentioned 
study. In another study on 222 Chinese AML patients 
with APL, 5-year overall survival was 80.9% (16). In an 
evaluation of 1397 APL patients during 1975-2008 in 
the United States, 5-year overall survival showed a 
remarkable increase from 10% during 1975-1990 to 
64% during 2000-2008 (14). A report on 54 AML 
patients of M6 subtype in France showed 5-year survival 
of 17% with median overall survival of 9 months (17). 
Another research found that AML subjects with normal 
cytogenetics had a 5-year overall survival rate of 74% 
(18). The different survival rate of APL patients in our 
study compared with the studies in China and the United 
States can be attributed to multiple factors such as 
different supportive therapy protocols, late diagnosis in 
our patients and subsequently late initiation of 
chemotherapy, or even unknown genetic factors. 
Evaluation of these parameters and their extent of 
contribution to this low survival rate needs another 
comprehensive study to be addressed. 
Inconsistent results among different studies can be 
explained by different molecular and clinical 
characteristics of AML patients with t(15;17)(q22;q12). 
Besides, the role of therapeutic procedures is also of 
critical importance in the determination of survival in 
AML patients (19,20). Introduction of ARTA has been 
associated with an increased survival rate in 
t(15;17)(q22;q12) positive AML patients (16,21). 
ATRA induces differentiation in promyelocytes, and is 
considered a unique therapeutic approach among 
hematological malignancies. A high rate of 97% of 2-
year survival has been reported in t(15;17)(q22;q12) 
positive patients who received ATRA+ATO as 
induction therapy (22). Furthermore, early initiation of 
therapy has been shown to significantly affect survival 
rates in AML patients (23). It was shown that 10-year 
overall survival in AML patients who underwent 
allogenic bone marrow transplantation were 63% (24).  
In the present research, we found the highest rate of 
5-year survival in patients with 20-35 years old (47.6%), 
while the lowest rate (11.9%) belonged to patients with 
<20 and >50 years old.  An inverse relationship between 
survival and age at diagnosis has been noted in a 
majority of AML subtypes (2,16,25,26). Likewise, in a 
study carried out by Dores GM et al. on 1397 APL 
patients in the United States, age was suggested as the 
most prominent factor influencing survival, with a 
higher rate of 5-year survival reported for patients with 
20-39 years old (14). Similarly, it was demonstrated that 
younger Iranian AML patients had a higher 5-year 
survival rate (13,27). In another study from the United 
States, 5-year survival was shown to be <10% for AML 
patients older than 60 years old (2). Age was also 
suggested as a poor prognostic factor in a cohort of 5480 
AML patients aged 72-83 years old in the United States 
(23). In addition, Kent EE et al. found that children had 
better survival compared to adolescent-adults 
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considering all subtypes of leukemia (26). Furthermore, 
AML patients with >75 years old showed a higher risk 
of mortality than younger patients within 5 years (19). 
Redaniel MT et al. evaluated 54 AML patients of M6 
subtype in France, they found that age higher than 60 
years old rendered a poor prognosis (17).   
We observed that patients with lower leukocyte and 
higher platelet counts had better survival and lower 
mortality rates. The best survival was recorded for 
patients with WBC <10× 109/𝑙 and platelet count 
>140× 109/𝑙. A pervious study addressed leukocyte 
count at presentation as a prominent prognostic factor in 
t(15;17)(q22;q12) positive AML patients (16). In Iranian 
AML patients, WBC >10×109/ 𝑙 was associated with 
higher mortality rate, while WBC 5-10× 109/𝑙  
demonstrated the highest survival rate in these patients 
(27).  Likewise, Iranian patients with AML who were 
diagnosed with WBC> 20× 109/𝑙 showed a 
significantly lower rate of 5-year survival (25.6%) than 
patients with WBC <20× 109/𝑙 (49.1%) (13). 
 
Conclusion 
We observed that t(15;17)(q22;q12) cytogenetic 
abnormality was the most common AML subtype in 
north-east Iran. The survival rate of our patients was 
associated with factors such as the age at presentation 
and initial leukocyte and platelet counts. To improve 
survival rate of these patients, it is recommended to use 
more accurate diagnostic procedures and provide timely 
and effective therapeutic support. 
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